• Explore /
  • Poster
  • / Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.

Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.

Abstract Poster

Authors

null

Matthew D. Hellmann

Memorial Sloan Kettering Cancer Center, New York, NY

Matthew D. Hellmann, Scott Joseph Antonia, Ani Sarkis Balmanoukian, Julie R. Brahmer, Sai-Hong Ignatius Ou, Sang-We Kim, Myung-Ju Ahn, Dong-Wan Kim, Martin Gutierrez, Stephen V. Liu, Patrick Schoffski, Dirk Jaeger, Rahima Jamal, Joseph W. Leach, Guy Heinrich Maria Jerusalem, Jose Lutzky, John J. Nemunaitis, Yu Gu, Shaad Essa Abdullah, Neil Howard Segal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT01693562

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 169)

DOI

10.1200/JCO.2018.36.5_suppl.169

Abstract #

169

Poster Bd #

L2

Abstract Disclosures

Similar Posters

First Author: Ani Sarkis Balmanoukian

Poster

2017 ASCO Annual Meeting

KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.

KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.

First Author: Natasha B. Leighl

First Author: Noah M. Hahn

First Author: Edward B. Garon